Johnson & Johnson Reports the Results from 2 Trials of Nipocalimab to Treat Generalized Myasthenia Gravis (gMG) and Sjögren’s Disease (SjD)
Shots:
- Both the P-II (DAHLIAS) & P-III (VIVACITY) trials evaluated the safety & efficacy of Nipocalimab vs PBO in patients with gMG & SjD. The company expects to present the data from the trials at upcoming medical conferences
- In the P-III trial the study met its 1EP by achieving a statistically significant reduction in MG-ADL score from baseline from wk22-wk24 vs PBO whereas the P-II trial also met its 1EP by depicting a statistically significant reduction in clinESSDAI score from baseline at wk.24 vs PBO
- Nipocalimab is mAB that selectively blocks FcRn to reduce levels of circulating IgG Ab. Earlier in Dec 2021 Nipocalimab received the US FDA’s ODD for gMG along with other designations for other indications
Ref: Johnson & Johnson | Image: Johnson & Johnson
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
